Breaking News

Tizona Licenses Ligand’s OmniAb Transgenic Platforms

February 3, 2016

Will use OmniRat, OmniMouse and OmniFlic to generate fully human mono- and bispecific antibodies

Ligand Pharmaceuticals has entered into a worldwide license agreement with Tizona Therapeutics, an immunology company developing therapies for cancer and autoimmune disease, for its OmniAb transgenic animal platforms. Tizona will use the OmniRat, OmniMouse and OmniFlicplatforms to generate fully human mono- and bispecific antibodies. Ligand will be eligible to receive annual platform access payments and patent filing fees, and clinical milestones and royalties for each successful OmniAb antibody.

“We have now added Tizona as a new partner as they expand their immuno-oncology and inflammation drug discovery efforts,” said John Higgins, chief executive officer of Ligand Pharmaceuticals. “This is the second licensing deal struck by Ligand on OmniAb and the 18th commercial partner overall, which represents a strong continued momentum for the technology. We believe the OmniAb platform has great potential to enable the discovery and development of novel medicines to meet major medical needs.”
blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Top 25 Pharma and Biopharma Report

    Top 25 Pharma and Biopharma Report

    July 20, 2015
    (Based on 2014 Sales, in $U.S. Millions)

  • Heavy Metals in Drug Products

    Heavy Metals in Drug Products

    Nikki Schopp, Team Leader in charge of ICP-MS, ICP-OES and AA testing, SGS||January 29, 2015
    The potential presence of trace amounts of heavy metals in drug products is a real cause for concern with regulators.